{"denoms":[{"counts":[{"groupId":"BG000","value":"20"}],"units":"Participants"}],"groups":[{"description":"CONDITIONING REGIMEN: Cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.\n\nGRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Rituximab IV days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.\n\nTRANSPLANTATION: Allogeneic hematopoietic stem cell transplantation on day 0.\n\nlaboratory biomarker analysis: Correlative studies\n\ngraft versus host disease prophylaxis/therapy: Undergo graft versus host disease prophylaxis/therapy\n\ncyclophosphamide: Given PO or IV\n\nfludarabine phosphate: Given IV\n\nbusulfan: Given IV\n\ntotal-body irradiation: Undergo TBI\n\ngraft-versus-tumor induction therapy: Undergo graft-versus-tumor induction therapy\n\nimmunosuppressive therapy: Undergo immunosuppressive therapy","id":"BG000","title":"Treatment (Rituximab and Allogeneic HCT Transplant)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"21","upperLimit":"52","value":"39"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}